Search

Your search keyword '"Borbujo J"' showing total 517 results
Start Over Author "Borbujo J"
517 results on '"Borbujo J"'

6. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience

Author

Gimenez-Arnau, A, primary, Bartra, J, additional, Ferrer, M, additional, Jauregui, I, additional, Borbujo, J, additional, Figueras, I, additional, Muñoz-Bellido, FJ, additional, Pedraz, J, additional, Serra-Baldrich, E, additional, Tejedor-Alonso, MA, additional, Velasco, M, additional, Terradas, P, additional, and Labrador, M, additional

Published
2022
Full Text
View/download PDF

22. A Specialized Therapeutic Approach to Chronic Urticaria Patient’s Refractory to H1-Antihistamines Improves the Burden of the Disease. The Spanish AWARE Experience

Author

Gimenez Arnau, A., Bartra Tomàs, Joan, Ferrer, M., Jauregui, I., Borbujo, J., Figueras Nart, Ignasi, Muñoz Bellido, F. J., Pedraz Muñoz, Javier, Serra Baldrich, Esther, Tejedor Alonso, Miguel Ángel, Velasco, M., Terradas, P., and Labrador, M.

Subjects
Quality of life, Urticaria, Qualitat de vida, Urticària
Abstract

Objective: During its first year, the AWARE study assessed disease activity, patient quality of life (QOL), and treatment patterns in chronic urticaria (CU) refractory to H1-antihistamines (H1-AH) in clinical practice. Methods: We performed an observational, prospective (24 months), international, multicenter study. The inclusion criteria were age _>18 years and H1-AH-refractory CU (>2 months). At each visit, patients completed questionnaires to assess disease burden (Urticaria Control Test [UCT]), disease activity (7 day-Urticaria Activity Score [UAS7]), and QOL (Dermatology Life Quality index [DLQI], Chronic Urticaria Quality of Life Questionnaire [CU-Q2oL], and Angioedema Quality of Life Questionnaire [AE-QoL]). We present data for Spain. Results: The study population comprised 270 evaluable patients (73.3% female, mean [SD] age, 48.9 [14.7] years). At baseline, 89.3% were prescribed a CU treatment. After 1 year, first-and second-line treatments became less frequent and third-line treatments became more frequent. At baseline, 47.0% of patients experienced angioedema; at 1 year, this percentage had fallen to 11.8%. The mean (SD) AE-QoL score decreased from 45.2 (28.7) to 24.0 (25.8). The mean (SD) UCT score decreased from 7.0 (4.5) to 12.1 (4.1). According to UAS7, 38.2% of patients reported absence of wheals and itch in the previous 7 days at 1 year compared with 8.3% at baseline. The mean (SD) DLQI score decreased from 8.0 (7.4) to 2.8 (4.6). At the 1-year visit, the percentage of patients reporting a high or very high impact on QOL fell from 29.9% to 9.6%. Conclusions: H1-AH-refractory CU in Spain is characterized by absence of symptoms and a considerable impact on QOL. Continuous follow-up of CU patients and third-line therapies reduce disease burden and improve patients' QOL.

Published
2020

Catalog

Books, media, physical & digital resources
See catalog results